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atent Foramen Ovale,
uilty But Only as a Gang
ember and for a Lesser Crime*
ernhard Meier, MD, FACC, FESC
ern, Switzerland
n the third century (1,2) of arguing whether a patent foramen
vale (PFO), caught repeatedly in the act of begetting para-
oxical thromboembolism (PTE) (3–5), poses a significant
hreat, some facts seem straightforward; some do not. A
FO is required before birth. The fetal right ventricle is not
apable of pumping all of the blood through the collapsed
ungs. Birth changes this, as the passage through the lungs
ecomes mandatory and is facilitated by decreased pulmo-
ary vascular resistance. The Eustachian valve (6) (Fig. 1) or
Chiari’s network (7) (ridge or transatrial membrane,
espectively, canalizing the blood from the inferior vena cava
nto the PFO) are no longer required. On the contrary, they
re now counterproductive, impeding fusion of the PFO
hat should occur at this stage. If these anatomical structures
ersist and remain directed onto a PFO, they constitute
ignificant risk factors. The same holds true for an atrial
See page 440
eptal aneurysm (ASA). This misnomer is used to describe
thin-walled, flaccid, and undulating portion of the septum
rimum in the region in which it is overlying the septum
ecundum on the left side, the site that is supposed to fuse
fter birth (Fig. 2). Individuals with an ASA have a higher
revalence of a PFO, proved again by Meissner et al. (8) in
his issue of the Journal and trivial to every handyman
nowing that it is difficult to glue two structures together
hat are constantly moving to and from each other. The
FO with an ASA also is likely to open more often and
ore widely. A curtain will yield more easily to a draft than
solid door ajar.
The PFO and its accomplices have been under tightening
crutiny as a remediable cause for PTE (9–16). Initially, it
as the ASA that caught the attention, when transthoracic
chocardiography became capable of demonstrating it in
atients with otherwise-unexplained cerebral vascular em-
olic accidents. Its role in PTE was confirmed in individual
eports (17) as well as in meta-analyses (18). In the era
efore transesophageal echocardiography improved the sen-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiology, Swiss Cardiovascular Center Bern, Universityp
ospital, Bern, Switzerland. Dr. Meier has acted as proctor for a honorarium for
everal devices for PFO closure.itivity to document a PFO, the ASA was assumed to
roduce embolism even in the absence of a PFO. This
isconception has since been discarded for good (17).
orrespondingly, it has been shown that closure of the PFO
n patients with an ASA removes the clinical relevance of
he latter (19).
The importance of the isolated PFO remains controver-
ial. In limited patient cohorts observed for only a few years,
he risk of a recurrent cerebrovascular event after an index
vent appears not significantly increased by the presence of
PFO (17). This issue’s survey on 577 random participants
45 years) of the Stroke Prevention: Assessment of Risk in
Community (SPARC) study with PFO screening by a
ingle echocardiographer duplicates this impression (8).
ven when looking specifically at large-size PFOs, a signif-
cant risk for cerebrovascular events could not be detected.
he number of such individuals was, however, small (n 
3). The prevalence of an ASA was 1.1% (5 of 437 subjects)
n subjects without PFO and 4.3% (6 of 140 subjects) in
hose with PFO. The fact that an ASA increases the risk of
ersistence of the foramen ovale was confirmed with a
ignificance of 0.028. Cerebrovascular events, including
ransient ischemic attacks (TIAs), occurred in 41 subjects
approximately 1.4 events per 100 observation years, assum-
ng a five-year mean observation period). The cohort with a
FO were afflicted by 12 such events (1.7 per 100 observa-
ion years). Subjects without a PFO were afflicted by 29
uch events (1.3 per 100 observation years). The actuarial
vent-free survival at five years was 91% with and 93%
ithout a PFO (not significant). It was 81% for subjects
ith an ASA and 93% for those without. This nearly
our-fold risk difference reached statistical significance (p 
.048) after correction for baseline variables, albeit based on
wo events only. Surprisingly, these two events happened in
he six patients with ASA but no PFO, projecting their risk
t seven times that of the rest of the study population,
hereas the risk of an ASA with a PFO was nonexistent.
mall numbers must account for these findings, in stark
ontrast to current knowledge and logic.
The classical stroke risk factors, such as previous myocar-
ial infarction, atrial fibrillation, and diabetes, proved their
ssumed doom in this survey. A previous venous thrombo-
mbolism was not identified as a risk factor, which again
urns the focus away from the PFO.
However, the case against the PFO is far from an
cquittal. A meta-analysis had yielded an association of
FO with all strokes with an odds ratio of 3, which
ncreased to 5 if only cryptogenic strokes were considered.
he odds ratios for ASA admittedly were more drastic (16
nd 24, respectively) (18). The noncorrelation with the size
f the PFO in this study may be due to limited numbers or
nsensitive assessment methods. It contradicts previous art.
natomic PFO size (6), amount of provoked shunting (20),
nd the presence of spontaneous right-to-left shunt (21) all
roved to be significantly linked to cryptogenic stroke.
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January 17, 2006:446–8 Editorial Commentoreover, compelling echocardiographic documents of
hrombi straddling the PFO (3–5) and strokes or myocar-
ial infarctions in healthy young people with nothing but an
minously gaping PFO cannot be dispensed lightly.
Admittedly, the yearly recurrence rates of a cryptogenic
troke in the presence of a PFO under medical treatment
ith acetylsalicylic acid or warfarin reported from 16% to
% (12,22,23) may have been overly pessimistic considering
hat, typically, people age 55 years were studied. Yet,
ncluding TIAs it had been 10% with and 8%, respectively,
ithout a PFO in a substudy of the Warfarin Aspirin
ecurrence Stroke Study (WARSS) (24) with a mean age of
3 years, comparable with the 67 years in the survey by
eissner et al. (8).
The potential of a PFO to cause harm increases with age
arallel to the occurrence of venous thromboembolism
igure 1. Eustachian valve (EV) demonstrated by transesophageal echocard
p, feet down). The EV directs blood from the inferior vena cava (IVC) dir
nd septum primum [SP] outlined by the connector of the two disks of an
trium.
igure 2. Atrial septal aneurysm in a transesophageal echocardiogram
head right, feet left) displayed in superimposed maximum excursion
. . .) to the left atrium (LA) and the right atrium (RA), respectively, ofr
he thin and mobile septum primum. There is also an Eustachian valve
EV). IVC  inferior vena cava; SS  septum secundum.25,26). Correspondingly, WARSS only showed a signifi-
ant correlation between PFO and cryptogenic stroke re-
urrence in patients65 years but not in those ages 55 to 64
ears (26).
Another hard-to-overlook piece of evidence for the po-
ential of evil of a PFO in the presence of venous thrombosis
s the fact that the stroke rate in patients admitted for
linically apparent pulmonary embolism was 13% with and
nly 2% without a PFO (p  0.02) with a mortality of 33%
nd 14%, respectively (p  0.01) (27). Moreover, analyzing
he benefit of closing the PFO percutaneously in contrast to
edical treatment in a meta-analysis of nonrandomized
rials, the annual rate of stroke was reduced from 3.1% to
.4%, that of TIA from 2.6% to 1.4%, and that of either
rom 5.8% to 1.9% (p  0.05 for all) (23).
Assuming the role of the prosecutor with the PFO on
rial, one could cast in front of the jury the evidence of a
ayo Clinic autopsy series (28). The almost linearly de-
reasing prevalence of a PFO with age could indicate a
elective mortality rather than a tendency for spontaneous
losure of the PFO as assumed by the authors. That would
all for early detection and closure of all PFOs or at least the
gly ones, before venous thrombosis kicks in during early
dulthood. Cross your heart, if a simple vaccination against
he PFO was available, would you not recommend it for
verybody or, if it was not completely free of side effects,
dvocate early screening and vaccination in case of a
ocumented PFO?
In the want of such a vaccination, general screening, at
east for large PFOs associated with an ASA, appears pressing
very time one is confronting a young person with irrepa-
able damage from a stroke that has to be considered
aradoxical for lack of any plausible cause short of the PFO
ound in the aftermath. It has to be conceded that there is
ore to cryptogenic systemic embolism than a PFO as such
s not found in all cases. If there is no PFO or other
phy (left) and contrast fluoroscopy (right) in an identical projection (head
nto the patent foramen ovale (PFO) (gap between septum secundum [SS]
latzer 25 mm PFO occluder on the right). LA  left atrium; RA  rightiogra
ectly o
Ampight-to-left passage, perhaps the pulmonary venous bed
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Editorial Comment January 17, 2006:446–8hould be suspected. It constitutes one of the remaining
lind spots in modern medicine. Lacking techniques to
heck for pulmonary venous thrombi and in light of ex-
remely simple, safe, and reliable percutaneous, catheter-
ased methods to close a PFO permanently in 15 min
ith the awake patient being incapacitated for2 h, we will
ontinue to be tempted to pound on the nail with this
legant hammer. We just have to make sure that we pound
n nothing but nails (e.g., PFOs that deserve this denom-
nation), not to fall into Mark Twain’s category of men with
hammer for whom everything looks like a nail to pound
pon.
Notwithstanding, the report of Meissner et al. (8) pro-
ides an important hint to the fact that ongoing randomized
rials on this subject with target patient numbers of 500 to
,500 and follow-up periods of just a couple of years may be
latantly underpowered. They risk falling short of showing
hat a good thing is a good thing. While waiting for their
esults after perhaps expanded recruitment and extended
ollow-up, we better keep the PFO in custody using match-
ontrolled, nonrandomized data for justification (29,30). It
s more likely than not that, in the end, the PFO will be
onvicted, even though only as a member of a gang (i.e.,
SA, Eustachian valve, Chiari’s network, venous thrombo-
is, right atrial pressure overload, hypercoagulability) and for
lesser crime.
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